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Background: Corticosteroids have been administered prophylactically for more than
60 years in pediatric heart surgery, however, their use remains a matter of debate.
There are three main indications for corticosteroid use in pediatric heart surgery with the
use of cardiopulmonary bypass (CPB): (1) to blunt the systemic inflammatory response
(SIRS) induced by the extracorporeal circuit; (2) to provide perioperative supplementation
for presumed relative adrenal insufficiency; (3) for the presumed neuroprotective effect
during deep hypothermic circulatory arrest operations. This review discusses the current
evidence behind the use of corticosteroids in these three overlapping areas.
Materials and Methods: We conducted a structured research of the literature using
PubMed and MEDLINE databases to November 2017 and additional articles were
identified by cross-referencing.
Results: The evidence suggests that there is no correlation between the effect of
corticosteroids on inflammation and their effect on clinical outcome. Due to the limitations
of the available evidence, it remains unclear if corticosteroids have an impact on
early post-operative outcomes or if there are any long-term effects. There is a limited
understanding of the hypothalamic-pituitary-adrenal axis function during cardiac surgery
in children. The neuroprotective effect of corticosteroids during deep hypothermic
circulatory arrest surgery is controversial.
Conclusions: The utility of steroid administration for pediatric heart surgery with
the use of CPB remains a matter of debate. The effect on early and late outcomes
requires clarification with a large multicenter randomized trial. More research into
the understanding of the adrenal response to surgery in children and the effect of
corticosteroids on brain injury is warranted.
Keywords: corticosteroids, clinical outcomes, relative adrenal insufficiency, deep hypothermic circulatory arrest,
pediatric heart surgery, cardiopulmonary by-pass
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INTRODUCTION
The introduction of the cardiopulmonary bypass (CPB) circuit
in the mid-50s made the surgical treatment of intracardiac
lesions possible and led to a rapid progress in the field of
cardiac surgery [1]. However, CPB is also known to provoke
a systemic inflammatory response (SIRS) due to the contact of
blood with the extracorporeal circuit, ischemic reperfusion injury
of the heart or endotoxemia due to increased gut permeability.
This systemic activation is potentially beneficial because it
triggers an immune response that could prevent infection and
promote healing, but can also prove detrimental and thus
result in organ dysfunction and even death [2]. Therefore,
since the introduction of the CPB, various strategies have been
employed to modulate this SIRS with an aim to improve clinical
outcomes. Such strategies include the use of glucocorticoids,
aprotinin, antioxidants, and miniaturized or heparin-coated
bypass circuits [3]. Furthermore, in pediatric heart surgery,
the modulation of SIRS is of greater importance because
it is believed that the inflammatory response is augmented
by the surface of the extracorporeal circuit relative to the
reduced circulating blood volume, the more frequent use of
the deep hypothermic circulatory arrest (DHCA) and the more
pronounced hemodilution [4] compared with procedures in
adults. The use of corticosteroids in cardiac surgery began
in the 1960s [5] and according to several current surveys
of clinical practice, corticosteroids are still widely used in
pediatric heart surgery that involves CPB [6, 7]. By contrast,
in adult heart surgery, the use of prophylactic corticosteroids
is no longer routine because of no clear evidence backing
their administration. The DECS trial recruited 4,494 adult
patients undergoing CPB surgery and found no impact of a
single intraoperative dose of dexamethasone (1 mg/kg) on the
composite end-point of death, myocardial infarction, stroke,
renal failure and respiratory failure at 30 days. However, in the
same study, dexamethasone was associated with reductions in
postoperative infection, duration of mechanical ventilation and
length of intensive care and hospital stays [8]. In the largest study
of corticosteroids vs. placebo in adults to date, the SIRS trial,
7,507 patients were randomly assigned to methylprednisolone
250mg at anesthetic induction and 250mg at the initiation of
CPB, or placebo [9]. Corticosteroids had no impact on the risk of
death or major morbidity including infection, length of hospital,
intensive care stay, respiratory, or renal failure.
The prophylactic use of corticosteroids in pediatric cardiac
surgery population continues to be a matter of debate likely
due to the lack of well-designed, large randomized controlled
trials (RCTs) that can detect a treatment effect in the context of
the current low perioperative mortality and morbidity. However,
corticosteroids are also given in pediatric heart surgery to
protect against the so-called relative adrenal insufficiency that can
accompany the acute stress of surgery [10, 11]. Due to a lack
of basic understanding of hypothalamic-pituitary-adrenal axis
physiology during and after pediatric heart surgery, the evidence
is limited in this area [12]. Finally, another potential use of
corticosteroids in pediatric heart surgery is for their potential
neuroprotective effect during DHCA procedures. In the current
review, we will discuss the evidence and controversies around
these three main indications of steroid use in pediatric heart
surgery. We will discuss these topics separately, although their
pathogenesis is interconnected.
MATERIALS AND METHODS
We conducted a structured research of literature using PubMed
and MEDLINE databases. The search strategy included
a combination of the terms: “steroid,” “glucocorticoid,”
“corticosteroid,” “dexamethasone,” “hydrocortisone,”
“methylprednisolone,” “pediatric,” “pediatric,” “heart surgery,”
“cardiac surgery,” “children,” “neonates,” “deep hypothermic
circulatory arrest,” “adrenal.” The last search was conducted
in November 2017. Additional articles were identified by
cross-referencing from author reference lists and published
review papers. We have included all articles assessing the effect
of corticosteroids on inflammation, clinical outcomes, adrenal
function and brain injury in children undergoing heart surgery
with use of CPB.
RESULTS
Corticosteroids, Inflammation, and Clinical
Outcomes
Many studies have attempted to correlate markers of
inflammation after glucocorticoid administration with clinical
outcomes [13–26]. Firstly, it is well known that SIRS is a
multifaceted, complex response that is challenging to characterize
and modulate. Therefore, measuring only a few cytokines might
not be accurate enough in view of the complex array of pro-
inflammatory and anti-inflammatory mediators that are released
during the SIRS process [27]. Secondly, while glucocorticoids can
blunt inflammation, but this does not necessarily translate into
improved short-term clinical outcomes [17, 25, 28]. Moreover,
a study by Gessler et al. found no impact of glucocorticoid
administration on markers of inflammation [18]. Graham et
al. in an RCT of 68 children undergoing surgery with use
of CPB found no effect single vs. 2-dose corticosteroids on
inflammation [29]. Finally, there is some evidence that the
host inflammatory response plays an important role and that
clinicians should approach SIRS in a personalized rather than
standardized manner. Huber et al. [30], in a study of 37 children
undergoing heart surgery with use of CPB, demonstrated that
the neutrophil phenotype signature could predict end-organ
dysfunction associated with SIRS.
Several small-sized RCTs have focused on the effect of
corticosteroids on clinical outcomes in the pediatric population
(Table 1). Most of these trials measure inflammation parameters
and the clinical data is measured either as a primary or secondary
outcome. All have in common a small sample size and significant
variability in the type and regimen of corticosteroid used. The
first randomized controlled trial of corticosteroid (47 children)
vs. placebo (48 children) was published by Toledo-Pereyra et
al. in 1980. The authors reported improved survival in patients
administered methylprednisolone 30 mg/kg: 1 h preoperatively,
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5min pre-CPB and every 6 h for 24 h; however, there was no
correlation with other biochemical markers [31]. Bronicki et
al. in an RCT of 29 children, found dexamethasone given 1
mg/kg, 1 h prior to CPB, was associated with lower alveolar-
arterial gradients, lower fluid requirement and less mechanical
ventilation [32]. In an RCT of 30 children, Varan et al.
compared the dose-effect of methylprednisolone 30 mg/kg to
methylprednisolone 2 mg/kg both given by intravenous infusion
pre-CPB. There was no difference in clinical outcomes between
the two groups (ventilation time, intensive care unit stay or
oxygenation) [15]. Later, Lindberg et al. in an RCT of 40 children
found no effect of dexamethasone 1 mg/kg after anesthesia
induction on oxygenation, fluid balance, critical care stay, or
ventilation time [17]. Schroeder et al in an RCT of 29 children,
compared the effect of 30 mg/kg of methylprednisolone double-
regimen (pre-operatively and intraoperatively) to a single dose
(30 mg/kg) intraoperatively. The double-dose steroid recipients
had better oxygenation, lower body temperature and reduced
fluid requirements [16]. Checchia et al. reported in an RCT
of 28 children no effect dexamethasone 1 mg/kg, given 1-h
pre-CPB on sternal dehiscence rates, reoperation for bleeding,
or gastrointestinal bleeding [33]. Ando et al. in small RCT of
20 patients found a benefit of hydrocortisone administration
in terms of reduced body edema, improved oxygenation and
reduced duration of ventilation [34]. Graham et al. randomized
a total of 76 patients to either single (intraoperative) or double
dose methylprednisolone (8-h pre-operative and intraoperative).
The two-dose steroid group had a higher serum creatinine
and poorer postoperative diuresis [20]. There was no difference
in the incidence of low cardiac output syndrome, inotropic
requirement, duration of mechanical ventilation, ICU, or hospital
stay. Heying et al. evaluated the effect of dexamethasone 1
mg/kg 4 h pre-CPB in 20 neonates undergoing arterial switch
and found no effect of corticosteroids in terms of postoperative
cardiac parameters (heart rate, mean arterial pressure, central
venous pressure), diuresis, or oxygenation. However, there was
reduced dobutamine requirement 4 h post CPB [23]. Keski-
Nisula et al. in an RCT of 40 neonates undergoing surgery with
use of CPB, found no effect of 30 mg/kg of methylprednisolone
given at induction of anesthesia on postoperative lactate, central
venous saturation, inotropic score, duration of ventilation, or
survival; however, the steroid arm had significantly increased
blood glucose [25]. The same group investigated in a three-arm
RCT of 45 children the effect of 30 mg/kg methylprednisolone
after induction vs. 30 mg/kg methylprednisolone in prime vs.
placebo. There were no differences between the three groups,
in terms of lactate, inotropic score, duration of ventilation and
intensive care stay but the steroid-treated arms had higher blood
glucose compared to placebo [35]. Amanullah et al. in RCT of 152
children investigated the effect of dexamethasone 1 mg/kg given
at three time-points (induction, pre-CPB and 6 h from the last
dose) vs. placebo [28]. There was no difference between the two
arms in terms of ventilation times, urine output, mean systolic
and diastolic pressure, central venous pressure, inotrope score at
6 h and fluid requirement. An RCT of corticosteroid vs. placebo
in 190 neonates undergoing heart surgery with use of CPB, has
recently finalized recruitment and hopefully will inform us more
on this matter and others [36]. Another larger RCT of 1,200
neonates is currently recruiting patients1.
Several studies have attempted to quantify the effect of
glucocorticoids on markers of myocardial injury [23, 25, 33, 35,
37, 38].However, measuring these markers around the time of
cardiac surgery is both difficult to interpret and correlate with
clinical outcomes (see Table 2). In the adult population, the SIRS
trial demonstrated that the corticosteroid treated arm had an
increase in myocardial injury as measured by elevation of the
CK-MB enzyme compared with placebo [9].
In view of the limitations of the existing RCT evidence
discussed above, the available meta-analyses should be
interpreted with caution. The Cochrane meta-analysis by
Robertson-Malt et al. concluded that corticosteroids do not
significantly reduce post-operative complications as measured
by length of stay in ICU, peak core temperature and duration of
ventilation [39]. A more recent meta-analysis by Scrascia et al.
concluded no significant effect of corticosteroids on mortality,
mechanical ventilation time or ICU length of stay. Based only
on 15 patients, the authors found a reduced prevalence of renal
dysfunction associated with the use of steroid (13 vs. 2 patients)
[40].
In addition to the number of small-sized randomized trials
already discussed, several larger observational studies are worth
discussing here (Table 3). The Pasquali et al. [41, 42] studies
provide us with the largest sample despite their retrospective
design. In a registry data-base study of 46,730 patients, of
which 54% received perioperative corticosteroids, there was no
difference in mortality or ventilation times, however steroid use
was associated with increased length of stay, higher incidence of
infection and greater use of insulin. In the analysis stratified by
a congenital cardiac risk score (the RACHS-1 score), increased
morbidity associated with steroid use was more evident in
the lower risk categories (e.g., 1–3) [41]. Later, the same
group published a multicenter database study focused on
3,180 neonates and found corticosteroids to be associated with
increased infection across all regimens in the lower risk groups.
[42]. An observational study by Mastropietro et al. on 76
children undergoing complex heart surgery found that a greater
cumulative duration of steroid administration was associated
with higher risk of postoperative infection [43].
Indeed, neonates have been the focus of multiple studies
because they are considered to be the most vulnerable to CPB
insult. This may be due not only to the immaturity of the
HPA axis [11] but neonates also appear to display a distinct
inflammatory response compared to older age groups [44].
However, a recent best evidence topic review by our group could
not find a clear clinical benefit of corticosteroid in neonates
mainly due to the limitations in the available evidence, as
discussed earlier [45].
Dreher et al. [46] in a retrospective single-center database
study, compared the effect of methylprednisolone administration
in 303 children undergoing heart surgery during the 6 months
prior to discontinuation of steroid use with a cohort of 222
1STeroids to REduce Systemic Inflammation After Neonatal Heart Surgery
(STRESS). Available online at: https://clinicaltrials.gov/ct2/show/NCT03229538
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children were no glucocorticoid was used. Overall, the steroid
group had more wound infection and more respiratory failure
requiring tracheostomy. There were no differences in the rest
of the clinical outcomes (early mortality, ventilation time, renal
failure etc.,). In the neonate subgroup analyses, no difference in
clinical outcomes was detected. Using datasets from a clinical trial
(the Pediatric Heart Network’s Single Ventricle Reconstruction
trial), on neonates that had the Norwood procedure, Elhoff
et al. [47] compared the effect of intraoperative corticosteroid
administration in 498 recipients with 51 non-recipients and
found in the multivariate analysis no effect of corticosteroid on
lengths of stay but a trend toward better hospital survival in non-
recipients. This is one of the few studies where the authors have
also looked at the neurodevelopment outcomes at 14 months and
found no difference. A major limitation in the current studies
of the impact of corticosteroids on the clinical outcomes of
pediatric heart surgery is the lack of long-term follow-up of
the effect of corticosteroid administration on late neurocognitive
outcomes. In other patient groups, the early administration of
corticosteroids had detrimental effects. In an RCT of 262 infants
with severe respiratory distress syndrome requiring mechanical
ventilation, dexamethasone 0.25 mg/kg given every 12 h for 1
week was associated with adverse effects on the neuromotor and
cognitive function at school age [48].
In conclusion, most studies conclude that corticosteroids
dampen the SIRS to surgery. The effect of corticosteroids
on clinical outcomes has been studied in several small-sized
RCTs with conflicting evidence. Some studies show a beneficial
effect on clinical outcomes such as ventilation, oxygenation or
renal function parameters while in other studies, the use of
corticosteroids had no effect at all. Apart from being small-
sample sized, these studies used various types of steroid and
regimens, therefore, it is difficult to draw any valid conclusions.
A few large registry studies have raised concerns about the
association of corticosteroid administration with infection,
however, their results remain limited by their retrospective
design.
Relative Adrenal Insufficiency
Another justification for the use of corticosteroids is the so-
called relative adrenal insufficiency or adrenal cortex exhaustion,
originally described during critical illness or sepsis. According
to this definition, the adrenal response and subsequent
concentration of plasma cortisol is not adequate to cope
with the stress of surgery [49, 50]. Therefore, it is thought
that perioperative steroid supplementation could compensate
for this potential deficit. However, defining relative adrenal
insufficiency during critical illness remains a matter of debate.
The most commonly used diagnostic criteria in the literature
for adrenal insufficiency during critical illness or surgery is the
ACTH stimulation test described by Anane et al. In this test,
synthetic ACTH (Synacthen, cosyntropin, tetracosactrin) is given
intravenously. Cortisol is measured before Synacthen injection
and after, at 30 and 60min respectively. In 189 consecutive
adult patients with septic shock, the authors found that an
incremental cortisol response to ACTH (defined as the difference
between the basal cortisol and the highest value between cortisol
measured at 30 and 60min) of <9 µg/dL or a high baseline
cortisol concentration (>34 µg/dL) were of good prognostic
value for identifying patients at risk of death [50]. However,
this test is based on a few time-point value measurements of
cortisol. Therefore, this could prove inaccurate in the context
of a dynamic, pulsatile cortisol secretion that was described
in both healthy volunteers or adults undergoing heart surgery
[51, 52]. The major limitation of the current literature aimed
at understanding the HPA axis function during pediatric heart
surgery is to try to correlate the findings of the ACTH test
with the measures of clinical outcome. Other limitations include
the measurement of only a few, random plasma cortisol levels,
the variability in the dose used for Synacthen testing and most
importantly the concomitant use of glucocorticoids at induction
that obscures the assessment of the HPA axis [11, 12, 53–65].
Adequate assessment of the HPA axis during surgery and critical
illness requires very frequent cortisol measurements [66].
Several studies have attempted to characterize dynamic HPA
axis physiology during surgery or critical illness in children
(Table 4). Kucera et al measured plasma cortisol at six time
points in 24 children of various ages (ranging from 2 months
to 15 years): the day before surgery, at the end of surface
cooling, at the lowest temperature during CPB, 10min after
rewarming, at the end of CPB and on the 8th day, postoperatively
[67]. They found the cortisol levels to be in the range of the
normal laboratory values with a trend toward increase during
rewarming. Anand et al measured cortisol levels at seven time
points in 15 neonates: pre-operatively, pre-CPB, during DHCA,
at 6, 12, and at 24 h. The peaks in cortisol secretion were recorded
before CPB and at the end of the operation, then, the cortisol
levels fell below preoperative values at 12 h [68]. Gajarski et al.
measured cortisol at 10 time-points in 58 children: baseline—
preoperative, time of surgery and every 6 h up to 48 h. They have
stratified the cortisol profiles by various patient groups: control
(non-bypass or non-cardiac surgery procedures), CPB only (no
DHCA), DHCA (no steroid used), and DHCA with steroid
administration. The cortisol and ACTH peaked within 2 h of
surgery but without differences between the groups. In 9 patients,
not from the DHCA-steroid group, they noted an elevated
ACTH-cortisol ratio that correlated with an elevated inotropic
score postoperatively [53]. In 21 neonates undergoing heart
surgery with use of CPB, Garcia et al. assessed the HPA axis with a
low dose ACTH stimulation test (1 µg) on day 1 postoperatively.
The patients that had a significant serum cortisol increase after
ACTH test (>50 mg/dL) also had a higher mean arterial blood
pressure at 48 h postoperatively. All patients included in the
study had dexamethasone 0.5 mg/kg midnight before surgery
and at induction [54]. In 38 neonates undergoing complex heart
surgery, Mackie et al. measured serum cortisol at 3 time-points:
preoperatively, at 24 and 48 h postoperatively. They found the
higher cortisol levels to be associated with greater atrial filling
pressure and lower cardiac index. Again, all patients received
methylprednisolone (30mg/kg) at induction [55].Wald et al. [56]
measured Synacthen stimulated total cortisol and corticosteroid
binding globulin levels preoperatively and postoperatively in 51
children undergoing surgery with use of CPB (subjects aged <2
years received 125 µg while subjects >2 years received 250 µg).
Lower CBG and increased free cortisol (>6µg/ml) correlated
with worse clinical outcomes (longer length of stay, longer
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ventilation time, increased fluid requirement). The authors found
that only 17.6% of the patient had a low baseline total cortisol and
all had a “normal” response to Synacthen. They concluded that
total cortisol is not a good measure of HPA axis function in this
setting. All patient received 1 mg/kg of dexamethasone before
CPB. Verweij et al. [64] in a retrospective analysis of 62 patients
with low cardiac output post pediatric heart surgery, found no
effect of hydrocortisone administration in patients with supposed
adrenal insufficiency (defined as basal cortisol <100 nmol/l).
Sasser et al. [65] in a retrospective analysis of 41 neonates found
that a postoperative serum cortisol level >10 µg/dL was not
associated with worse clinical outcomes (lactate measurements,
inotropic score, fluid requirement, arteriovenous saturation
difference, mean blood pressure, mean CV, mean heart rate or
ventilation time). Furthermore, there was no difference in steroid
responsiveness compared to the cortisol >10 µg/dL group,
among patients that had hemodynamic compromise and were
administered hydrocortisone, postoperatively. In a prospective
analysis of 119 children undergoing heart surgery Schiller et
al. measured cortisol levels pre-operatively and at 18 h after
surgery. All patients were given methylprednisolone (30 mg/kg)
at induction [63]. The authors defined adrenal insufficiency as
a measured postoperative cortisol level of <18.1 µg/dL or a
delta cortisol value of <9 µg/dL (e.g., postoperative cortisol
- preoperative cortisol). There was no significant correlation
between patients with adrenal insufficiency by this definition
and the procedure complexity (low or high). Furthermore, the
postoperative course (ICU stay ventilation time, lactate, urine
output) of children with adrenal insufficiency was not different
from the children with apparently normal adrenal function. A
study by Bangalore et al. assessed postoperative serum cortisol
levels at three time-points: immediately after surgery and in
the first and second postoperative mornings. The cortisol fell
significantly over the first 24 h. Higher postoperative cortisol
measurements were associated with increased morbidity. All
patients received methylprednisolone (30 mg/kg) at induction
[62]. Crow et al measured serum cortisol and dexamethasone
following 1 mg/kg of dexamethasone in 32 infants undergoing
cardiac surgery with CPB. They noted significant variability
in dexamethasone levels and grouped the patients into high
dexamethasone (>15 mg/dL) or low dexamethasone (<15
mg/dL) on arrival to ICU. Although the patients that had a
higher dexamethasone levels had more pronounced suppression
of endogenous cortisol compared to basal levels this did not
translate into any impact on clinical outcomes [61]. Teagarden
et al. reviewed 24 patients that underwent surgery for congenital
heart disease and found that lower pre-hydrocortisone cortisol
concentrations were associated with improved hemodynamics
after hydrocortisone administration [58]. Maeda et al. classified
32 neonates undergoing heart surgery into patients with adrenal
insufficiency (baseline cortisol <15 µg/dL or incremental
increase after testing of <9 µg/dL and baseline cortisol of 15–34
µg/dL) and a group with normal adrenal function, after ACTH
test (3.5 µg/kg of tetracosactide acetate). All patients received
perioperatively 1 mg/kg hydrocortisone every 6 h up to 18 h
from first hydrocortisone dose. Only the patients diagnosed with
adrenal insufficiency exhibited a significant increase in mean
blood pressure and urine output in response to hydrocortisone
administration [59]. A recent study by Crawford et al. [57]
aimed to correlate relative adrenal insufficiency to clinical
outcomes in 40 neonates undergoing complex heart surgery. Like
the studies discussed above, all patients received preoperative
methylprednisolone. The authors defined adrenal insufficiency
as <9µg/ml increase in cortisol at 30min post ACTH test
(cosyntropin 1 µg). Five percent of the patients had adrenal
insufficiency post-CPB and this was significantly associated with
increased serum lactate and higher inotrope requirement.
We still do not have an accepted definition of adrenal
insufficiency in children undergoing heart surgery, hence it is
difficult to draw conclusions about the effect of corticosteroids
on adrenal function and clinical outcomes. Most of the studies
so far have used very few time-point measurements, with
conflicting results and were undertaken in children that received
corticosteroids at induction, therefore, making an accurate
assessment of the HPA axis almost impossible.
Corticosteroids and Cerebral Protection
Cardiac surgery with use of deep hypothermic circulatory
arrest is known to be associated with impaired cerebral oxygen
metabolism and cerebral edema [69, 70]. Corticosteroids are
used to treat cerebral edema secondary to brain tumors [71]
but are also used in the context of head trauma [72]. Therefore,
another justification for the use of corticosteroids is the use
for DHCA surgery. However, the CRASH trial showed an
increase in death at 2 weeks and 6 months with the use
of corticosteroids [72, 73]. The evidence of the impact of
corticosteroids on brain protection during the use of DHCA has
not been studied extensively and is limited to in vitro studies [74]
and a few in vivo experiments on piglets [69, 75] with conflicting
results.
Schmitt et al. investigated the effect of deep hypothermic
circulatory arrest on an in vitro model of mouse neonatal
astrocytes, neurons, and BV-2 microglia cells. The effect of
methylprednisolone (100 nM) was tested in cells that were
incubated according to a protocol that mimics the temperature
changes during pediatric deep hypothermic circulatory arrest:
deep hypothermia, slow rewarming and normothermia. The
authors measured in all cell lines the cytotoxicity and the
production of IL-6 as a marker for neuroprotection and
regeneration. While steroid administration had no effect in the
normothermic treated cells, in the deep hypothermia-treated
cells methylprednisolone increased cell survival but decreased the
protective IL-6 [74].
Langley et al. randomized two groups of 8 piglets to placebo
and intramuscular methylprednisolone 30 mg/kg, given 8- and
2 h before induction. All piglets underwent cooling to 18◦C,
60min of circulatory arrest and 60min of reperfusion and
rewarming. The steroid-treated arm had a significantly higher
recovery of cerebral blood flow and cerebral oxygen metabolism
[69]. In a later study, Schubert et al. randomized two groups
of seven neonatal piglets to intravenous methylprednisolone
(30 mg/kg), given 24 h before surgery vs. placebo. The piglets
were then cooled to 15◦C for a longer period of DHCA-
−120 min–before rewarming for 40min. The authors conducted
quantitative histological studies in the hippocampus, cortex,
cerebellum and caudate nucleus. Piglets in the steroid-treated
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arm had increased neuronal cell death and apoptosis in the
dentate gyrus of the hippocampus.
The neuroprotective potential of corticosteroids in cases of
pediatric heart surgery with use of deep hypothermic circulatory
arrest has therefore been the least studied. Current evidence is
contradictory and the results from the available animal studies
highlight the need for robust human trials aimed at this high-risk
patient subgroup.
CONCLUSIONS
We found no clear evidence that the anti-inflammatory effect
of corticosteroids translates into better clinical outcomes. Most
randomized studies in the literature report too few patients,
different endpoints and vary widely in the steroid type,
doses, and regimens. Although some registry studies examined
the effect of corticosteroids on larger patient populations,
they are limited by their retrospective design. The effect of
corticosteroids on clinical outcomes will need to be clarified
by a large, multicenter, randomized controlled trial with
clear agreed methodology and aims. Our knowledge about
the basic physiology of the hypothalamic-pituitary-adrenal
axis during surgery remains limited and it is unclear how
to define relative or absolute adrenal insufficiency in the
context of pediatric heart surgery. To comprehend this will
require understanding of the dynamic, pulsatile secretion
of adrenal cortisol which can only be gained from studies
that use frequent time-point measurements in patients not
receiving exogenous corticosteroids. Finally, the neuroprotective
effect of corticosteroids during deep hypothermic circulatory
arrest remains even more controversial and warrants further
research.
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